Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10585-014-9680-3.

Title:
Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone | Clinical & Experimental Metastasis
Description:
In prostate cancer metastases to bone, cancer cell-derived cytokines stimulate RANKL expression by cells of the osteoblast lineage, which in turn activates osteoclastic bone resorption. However, it is unclear whether cells of the osteoblast lineage signal back to prostate cancer cells, and if so, whether such direct cross-talk can be targeted therapeutically. Using the human prostate cancer cell line, PC3, we identified two novel signalling pathways acting between cells of the osteoblast lineage and cancer cells. First, exposure to RANKL stimulated the expression and release of IL-6 by PC3 cells in vitro (which is known to promote RANKL expression by osteoblasts). Second, treatment of PC3 cells with IL-6 increased the expression of RANK, the cognate receptor of RANKL, and enhanced the RANKL-induced release of IL-6 by PC3 cells. Third, targeted disruption of IL-6 signaling with tocilizumab, a clinically available antibody against the human IL-6 receptor, inhibited skeletal tumor growth in vivo and reduced serum RANKL levels as well as RANK expression by PC3-derived bone tumors. Similar effects were achieved when RANK expression was knocked down in PC3 cells. In contrast, disruption of IL-6 or RANK/RANKL signalling had no effect on PC3 tumor growth in soft tissues, indicating that these signalling pathways act specifically within the bone microenvironment. In conclusion, prostate cancer cells and cells of the osteoblast lineage communicate via two inter-dependent signaling pathways, which through auto-amplification strongly enhance metastatic prostate cancer growth in bone. Both pathways may be targeted for effective therapeutic intervention.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, pubmed, article, google, scholar, bone, cas, prostate, metastasis, cells, interleukin, rankl, growth, zheng, central, receptor, dunstan, seibel, cell, tumor, research, breast, clin, human, res, zhou, expression, metastases, metastatic, osteoclast, sydney, rank, vivo, access, guise, australia, privacy, cookies, content, signaling, markus, signalling, levels, pathway, factor, int, patients, survival, smith, university,

Topics {✒️}

nf-kappab/il-6 pathway month download article/chapter nuclear factor-kappab target inter-dependent signaling pathways nuclear factor-kappab inhibition hormone-independent prostate cancer parathyroid hormone-related protein castration-resistant prostate cancer bone-metastasis-free survival pc3-derived bone tumors de la taille t-cell-mediated regulation rank/rankl signalling full article pdf deficiency promotes growth enhances osteoclast formation metastatic breast cancer rankl acts directly rankl-independent mechanism tumor metastasis genes anti-tumour actions advanced prostate cancer prostate cancer foundation related subjects privacy choices/manage cookies osteosclerotic bone metastasis pc3 tumor growth signalling pathways acting signalling cross-talk ooi ll rankl-induced release prostate cancer cells prostate cancer progression promote rankl expression potentiates bone metastasis prostate cancer metastases prostate cancer patients interleukin-6 activates pi3 metastatic bone disease human il-6 receptor interleukin-6 enhances hypercalcemia tnf-alpha correlate cancer cell migration article zheng related bone metastases human il-6 responsible medical research council anzac research institute interleukin-6 receptor shedding bone resorption mediated

Questions {❓}

  • Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A (2007) The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone
         description:In prostate cancer metastases to bone, cancer cell-derived cytokines stimulate RANKL expression by cells of the osteoblast lineage, which in turn activates osteoclastic bone resorption. However, it is unclear whether cells of the osteoblast lineage signal back to prostate cancer cells, and if so, whether such direct cross-talk can be targeted therapeutically. Using the human prostate cancer cell line, PC3, we identified two novel signalling pathways acting between cells of the osteoblast lineage and cancer cells. First, exposure to RANKL stimulated the expression and release of IL-6 by PC3 cells in vitro (which is known to promote RANKL expression by osteoblasts). Second, treatment of PC3 cells with IL-6 increased the expression of RANK, the cognate receptor of RANKL, and enhanced the RANKL-induced release of IL-6 by PC3 cells. Third, targeted disruption of IL-6 signaling with tocilizumab, a clinically available antibody against the human IL-6 receptor, inhibited skeletal tumor growth in vivo and reduced serum RANKL levels as well as RANK expression by PC3-derived bone tumors. Similar effects were achieved when RANK expression was knocked down in PC3 cells. In contrast, disruption of IL-6 or RANK/RANKL signalling had no effect on PC3 tumor growth in soft tissues, indicating that these signalling pathways act specifically within the bone microenvironment. In conclusion, prostate cancer cells and cells of the osteoblast lineage communicate via two inter-dependent signaling pathways, which through auto-amplification strongly enhance metastatic prostate cancer growth in bone. Both pathways may be targeted for effective therapeutic intervention.
         datePublished:2014-09-16T00:00:00Z
         dateModified:2014-09-16T00:00:00Z
         pageStart:921
         pageEnd:933
         sameAs:https://doi.org/10.1007/s10585-014-9680-3
         keywords:
            Bone metastasis
            Prostate cancer
            Interleukin-6
            RANK
            RANKL
            Osteoblasts
            Cancer Research
            Biomedicine
            general
            Oncology
            Hematology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig6_HTML.gif
         isPartOf:
            name:Clinical & Experimental Metastasis
            issn:
               1573-7276
               0262-0898
            volumeNumber:31
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yu Zheng
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Dennis Basel
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
                     name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
                     address:
                        name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shu-Oi Chow
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Colette Fong-Yee
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sarah Kim
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frank Buttgereit
               affiliation:
                     name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT)
                     address:
                        name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
                        type:PostalAddress
                     type:Organization
                     name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
                     address:
                        name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Colin R. Dunstan
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
                     name:University of Sydney
                     address:
                        name:Department of Biomedical Engineering, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hong Zhou
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Markus J. Seibel
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
                     name:Concord Hospital
                     address:
                        name:Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone
      description:In prostate cancer metastases to bone, cancer cell-derived cytokines stimulate RANKL expression by cells of the osteoblast lineage, which in turn activates osteoclastic bone resorption. However, it is unclear whether cells of the osteoblast lineage signal back to prostate cancer cells, and if so, whether such direct cross-talk can be targeted therapeutically. Using the human prostate cancer cell line, PC3, we identified two novel signalling pathways acting between cells of the osteoblast lineage and cancer cells. First, exposure to RANKL stimulated the expression and release of IL-6 by PC3 cells in vitro (which is known to promote RANKL expression by osteoblasts). Second, treatment of PC3 cells with IL-6 increased the expression of RANK, the cognate receptor of RANKL, and enhanced the RANKL-induced release of IL-6 by PC3 cells. Third, targeted disruption of IL-6 signaling with tocilizumab, a clinically available antibody against the human IL-6 receptor, inhibited skeletal tumor growth in vivo and reduced serum RANKL levels as well as RANK expression by PC3-derived bone tumors. Similar effects were achieved when RANK expression was knocked down in PC3 cells. In contrast, disruption of IL-6 or RANK/RANKL signalling had no effect on PC3 tumor growth in soft tissues, indicating that these signalling pathways act specifically within the bone microenvironment. In conclusion, prostate cancer cells and cells of the osteoblast lineage communicate via two inter-dependent signaling pathways, which through auto-amplification strongly enhance metastatic prostate cancer growth in bone. Both pathways may be targeted for effective therapeutic intervention.
      datePublished:2014-09-16T00:00:00Z
      dateModified:2014-09-16T00:00:00Z
      pageStart:921
      pageEnd:933
      sameAs:https://doi.org/10.1007/s10585-014-9680-3
      keywords:
         Bone metastasis
         Prostate cancer
         Interleukin-6
         RANK
         RANKL
         Osteoblasts
         Cancer Research
         Biomedicine
         general
         Oncology
         Hematology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-014-9680-3/MediaObjects/10585_2014_9680_Fig6_HTML.gif
      isPartOf:
         name:Clinical & Experimental Metastasis
         issn:
            1573-7276
            0262-0898
         volumeNumber:31
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yu Zheng
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Dennis Basel
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
                  name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
                  address:
                     name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shu-Oi Chow
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Colette Fong-Yee
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sarah Kim
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frank Buttgereit
            affiliation:
                  name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT)
                  address:
                     name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
                     type:PostalAddress
                  type:Organization
                  name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
                  address:
                     name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Colin R. Dunstan
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
                  name:University of Sydney
                  address:
                     name:Department of Biomedical Engineering, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hong Zhou
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Markus J. Seibel
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
                  name:Concord Hospital
                  address:
                     name:Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical & Experimental Metastasis
      issn:
         1573-7276
         0262-0898
      volumeNumber:31
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
      address:
         name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT)
      address:
         name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
         type:PostalAddress
      name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
      address:
         name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Department of Biomedical Engineering, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:Concord Hospital
      address:
         name:Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yu Zheng
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Dennis Basel
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
            name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
            address:
               name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Shu-Oi Chow
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Colette Fong-Yee
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Sarah Kim
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Frank Buttgereit
      affiliation:
            name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT)
            address:
               name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
               type:PostalAddress
            type:Organization
            name:Charité University Medicine and German Rheumatism Research Center (DRFZ)
            address:
               name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Colin R. Dunstan
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
            name:University of Sydney
            address:
               name:Department of Biomedical Engineering, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Hong Zhou
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Markus J. Seibel
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
            name:Concord Hospital
            address:
               name:Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany
      name:Rheumatology and Clinical Immunology, Charité University Medicine and German Rheumatism Research Center (DRFZ), Berlin, Germany
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Department of Biomedical Engineering, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Department of Endocrinology and Metabolism, Concord Hospital, Sydney, Australia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(213)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

3.98s.